Lv11
30 积分 2022-04-26 加入
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
2小时前
待确认
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
2小时前
已完结
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
2小时前
已关闭
Salvage surgery and conversion surgery for patients with non-small cell lung cancer: A narrative review
5个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
5个月前
已完结
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
5个月前
已完结
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients
5个月前
已完结
A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC
5个月前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
5个月前
已完结
Prognostic value of surgical resection over biopsy in elderly patients with glioblastoma: a meta-analysis
6个月前
已完结
皖公网安备34019202002308
